| Name | Title | Contact Details |
|---|
Nurtur Health, Inc. is one of the leading companies in the Healthcare, Pharmaceuticals, and Biotech sector.
Swift Medical is the world leader in digital wound care management, delivering advanced wound care visualization and touchless 3D measurement through its smartphone-ready Swift Skin and Wound software. Swift`s enterprise-grade solution streamlines clinical and administrative wound care management workflows, from image capture and automatic risk scoring to assessment scheduling and claims submission. Today, Skin and Wound has been adopted by more than 4,000 facilities to monitor over 100,000 beds.
Hooper Holmes is a data-driven leader in collecting personal health data and transforming it into useful information, which in turn, enables our customers to take actions that manage or reduce their risks and expenses. As the foremost provider of risk assessment services for the insurance industry, we are the only company that can provide insurers with ALL the services they need to reach their ultimate goal: complete policy medical exam, data collection, laboratory testing, inspection reports and underwriting services in the industry. Each year we arrange more medical exams than any other company and process millions of specimens in our laboratory. And we provide a complete service for wellness, disease management, and managed care companies including scheduling support, fulfillment of supplies, blood collection kits, medical screenings, lab testing and data transmission.
intra-op monitoring services is one of the leading providers in Healthcare, Pharmaceuticals, and Biotech. It is based in Covington, LA. To find more information about intra-op monitoring services, please visit www.iomservices.com
KaloBios is a biopharmaceutical company dedicated to helping the lives of patients with innovative therapies. Our mission is to improve the lives of cancer patients with innovative, Humaneered®, monoclonal antibodies. KaloBios` Humaneered® antibodies are next generation, customized antibodies designed to overcome challenges limiting today`s marketed antibody products. Using our expertise, our antibodies are customized to enhance a desired effect or reduce a possible undesired effect. Our pipeline is comprised of Humaneered® antibodies. These antibodies are being investigated in clinical development programs focused on treating cancer: KB004 (anti-EphA3) Humaneered® mAb to treat patients with hematologic malignancies, solid tumors, and their stem cells; currently enrolling patients with myelofibrosis and myelodysplastic syndrome in the company’s Phase 2 expansion portion of its Phase 1/2 clinical trial in hematologic malignancies; and KB003 (anti-GM-CSF) Humaneered® mAb that KaloBios intends to evaluate in oncology indications where GM-CSF may play a key role in such indications as chronic myelomonocytic leukemia (CMML). KaloBios intends to commence clinical evaluation of KB003 in this patient population beginning in the second half of 2015. We use a patient-targeted approach utilizing or developing a screen or diagnostic method to identify those patients most likely to benefit from our treatments.